Glaukos CDO Tomas Navratil sells $251,120 in company stock

Glaukos Corp (NASDAQ:GKOS) Chief Development Officer Tomas Navratil executed three separate sales of company stock on October 5, 2026, totalling 1,527 shares valued at $251,120. The trades occurred at prices fluctuating between $163.93 and $165.60 per share, as per a Rule 10b5-1 trading plan initiated on June 12, 2026. The shares were divided into three sales: 888 shares at $163.93, 327 shares at $164.78, and 312 shares at $165.60.

This comes as Glaukos shares have soared 104% in the past year, presently trading at $172.18. Despite this, InvestingPro's analysis suggests the stock is currently overvalued. Mr. Navratil's ownership now stands at 69,291 shares, including 38,817 restricted stock units yet to vest. Glaukos, valued at $9.53 billion, has seen robust revenue growth of 41.6% but remains unprofitable with an EPS of -$3.25.

The company reported a stellar Q2 2026 earning of $185.6 million, surpassing the anticipated $151.5 million. Following the results, several firms revised their price targets: H.C. Wainwright to $195, Needham to $201, Stifel to $190, and Truist Securities to $215. Stifel maintained a Buy rating, predicting a potential $1.0 billion revenue for 2027, underpinned by the performance of its Epioxa, iDose, and Glaucoma products.